Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $48.6 million.

  • 4D Molecular Therapeutics' Cash & Equivalents fell 74.11% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 74.11%. This contributed to the annual value of $149.3 million for FY2024, which is 40.05% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Cash & Equivalents stood at $48.6 million, which was down 37.07% from $77.2 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Cash & Equivalents' 5-year high stood at $275.7 million during Q3 2023, with a 5-year trough of $48.6 million in Q3 2025.
  • Its 3-year average for Cash & Equivalents is $172.8 million, with a median of $187.5 million in 2024.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Cash & Equivalents soared by 375.84% in 2023 and then tumbled by 74.11% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Cash & Equivalents (Quarterly) stood at $153.0 million in 2021, then tumbled by 65.78% to $52.4 million in 2022, then spiked by 375.84% to $249.1 million in 2023, then slumped by 40.05% to $149.3 million in 2024, then tumbled by 74.11% to $48.6 million in 2025.
  • Its last three reported values are $48.6 million in Q3 2025, $77.2 million for Q2 2025, and $133.5 million during Q1 2025.